For individuals living with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a debilitating condition, the emergence of this treatment and the formulated version represents a genuine breakthrough . These groundbreaking therapies protect the transthyretin protein, halting its damaging build-up and lessening the severity of the illness. Patients are n